Get the Stockscreener App
4.41
1.12%
-0.05
After Hours:
4.44
0.03
+0.68%
Cytek Biosciences Inc stock is traded at $4.41, with a volume of 521.24K.
It is down -1.12% in the last 24 hours and down -1.56% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.46
Open:
$4.46
24h Volume:
521.24K
Relative Volume:
0.39
Market Cap:
$569.52M
Revenue:
$204.17M
Net Income/Loss:
$-74.00M
P/E Ratio:
-7.6364
EPS:
-0.5775
Net Cash Flow:
$-12.84M
1W Performance:
-3.71%
1M Performance:
-1.56%
6M Performance:
-14.86%
1Y Performance:
+19.51%
1-Day Range:
$4.365
$4.53
1-Week Range:
$4.365
$4.69
52-Week Range:
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.41 | 575.98M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences Inc (CTKB) Cash Flow - TradingKey
CTKB|Cytek Biosciences Inc|Price:4.420|Chg%:-0.040 - TradingKey
Cytek Biosciences, Inc. Revenue Breakdown – FWB:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences Inc (CTKB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making - Traders Union
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
CTKB stock rises as Cytek BioSciences reports revenue and margin trends - Ad-hoc-news.de
Cytek Biosciences to report Q2 2026 results on August 5 - scanx.trade
Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5 - Stock Titan
Cytek Biosciences reveals special summer incentive for reagent customers - Traders Union
Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus - Ad-hoc-news.de
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - BioSpace
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - Finviz
Cytek Biosciences Opens Innovation Center in Washington - marketscreener.com
Cytek Biosciences Opens Bellevue Innovation Center to Advance R&D and Customer Engagement - Quiver Quantitative
Cytek's Valerie Barnett exits as Chief Legal Officer; consulting role agreed - TradingView
Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms - Stock Titan
BlackRock, Inc. Reduces Stake in Cytek Biosciences Inc - GuruFocus
Cytek Biosciences announces webinar on accelerating human T-cell biology research - Traders Union
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences - Stock Titan
Cytek Biosciences expands flow cytometry footprint amid growing immunology demand - Ad-hoc-news.de
CTKBCytek BioSciences Inc Latest SEC Filings - Finviz
If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB) - Stock Titan
Cytek Biosciences explores growth paths as investors weigh long-term potential - ad-hoc-news.de
Cytek Biosciences (CTKB) Edges Higher as Shares Stabilize Near SupportWeekly Profile - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider - Stock Titan
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from Russell 2000 Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to sales forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB - TradingView
Cytek Biosciences (CTKB) Holds Steady Near Support as Volume Tells the StoryLiquidity Sweep - dars.gov.et
CTKB Forecast — Price Target — Prediction for 2027 - TradingView
8EQ Forecast — Price Target — Prediction for 2027 - TradingView
Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB) - TradingView
Cytek Biosciences Announces Chief Legal Officer Transition - The Globe and Mail
Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ) - TradingView
Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary - TradingView
Cytek Biosciences (NASDAQ: CTKB) legal chief exit detailed - Stock Titan
Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 1000 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 Health Care - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 - marketscreener.com
Cytek Biosciences Stockholders Back Board, Pay and Auditor - The Globe and Mail
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets - Yahoo Finance
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):